Zhejiang Jolly Pharmaceutical Co.,LTD

SZSE:300181 Stock Report

Market Cap: CN¥11.1b

Zhejiang Jolly PharmaceuticalLTD Future Growth

Future criteria checks 5/6

Zhejiang Jolly PharmaceuticalLTD is forecast to grow earnings and revenue by 20.8% and 22% per annum respectively. EPS is expected to grow by 20.8% per annum. Return on equity is forecast to be 21.4% in 3 years.

Key information

20.8%

Earnings growth rate

20.8%

EPS growth rate

Pharmaceuticals earnings growth18.5%
Revenue growth rate22.0%
Future return on equity21.4%
Analyst coverage

Low

Last updated20 May 2024

Recent future growth updates

No updates

Recent updates

Investors Still Aren't Entirely Convinced By Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Earnings Despite 32% Price Jump

Oct 17
Investors Still Aren't Entirely Convinced By Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Earnings Despite 32% Price Jump

These 4 Measures Indicate That Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Is Using Debt Safely

Oct 06
These 4 Measures Indicate That Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Is Using Debt Safely

It's A Story Of Risk Vs Reward With Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

Aug 30
It's A Story Of Risk Vs Reward With Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

We Ran A Stock Scan For Earnings Growth And Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Passed With Ease

Jul 29
We Ran A Stock Scan For Earnings Growth And Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Passed With Ease

Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Held Back By Insufficient Growth Even After Shares Climb 28%

May 13
Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Held Back By Insufficient Growth Even After Shares Climb 28%

A Look At The Fair Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

May 08
A Look At The Fair Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

There's No Escaping Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Muted Earnings

Mar 01
There's No Escaping Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Muted Earnings

Earnings and Revenue Growth Forecasts

SZSE:300181 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264,056811N/A8131
12/31/20253,232664N/A6921
12/31/20242,629547N/A6641
6/30/20242,359481245381N/A
3/31/20242,120428145294N/A
12/31/20231,942383157288N/A
9/30/20231,926356162349N/A
6/30/20231,922336137310N/A
3/31/20231,86130291245N/A
1/1/20231,805273141319N/A
9/30/20221,72325258260N/A
6/30/20221,65522875290N/A
3/31/20221,55720474290N/A
1/1/20221,457179104252N/A
9/30/20211,400158234319N/A
6/30/20211,322145269336N/A
3/31/20211,238122267327N/A
12/31/20201,09189221280N/A
9/30/20201,02449180222N/A
6/30/20209492982118N/A
3/31/202090126112148N/A
12/31/20199112688129N/A
9/30/201985934109160N/A
6/30/20197671439131N/A
3/31/201976423-5104N/A
12/31/201873021-7678N/A
9/30/201860920-12536N/A
6/30/201862931-41102N/A
3/31/201864743N/A20N/A
12/31/201767945N/A8N/A
9/30/201780449N/A114N/A
6/30/201781463N/A21N/A
3/31/201783059N/A54N/A
12/31/201684072N/A58N/A
9/30/201681986N/A22N/A
6/30/201681087N/A78N/A
3/31/201672085N/A112N/A
12/31/201567185N/A97N/A
9/30/2015657103N/A16N/A
6/30/2015620111N/A-18N/A
3/31/2015572107N/A-39N/A
12/31/2014515103N/A14N/A
9/30/201445794N/A13N/A
6/30/201444090N/A35N/A
3/31/201443185N/A42N/A
12/31/201341981N/A30N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300181's forecast earnings growth (20.8% per year) is above the savings rate (2.9%).

Earnings vs Market: 300181's earnings (20.8% per year) are forecast to grow slower than the CN market (23.5% per year).

High Growth Earnings: 300181's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 300181's revenue (22% per year) is forecast to grow faster than the CN market (13.3% per year).

High Growth Revenue: 300181's revenue (22% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300181's Return on Equity is forecast to be high in 3 years time (21.4%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y